Results 11 to 20 of about 33,910 (293)

Broadly Neutralizing Antibodies for HIV Eradication [PDF]

Current HIV/AIDS Reports, 2016
Passive transfer of antibodies has long been considered a potential treatment modality for infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV replication, however, were largely unsuccessful, as the antibodies that were studied neutralized only a relatively narrow spectrum of viral strains and were not very potent ...
Stephenson, Kathryn, Barouch, Dan
openaire   +6 more sources

Natural Evolution of Broadly Neutralizing Antibodies [PDF]

Cell, 2015
Wu et al. couple next-generation sequencing with structural analysis to illuminate the key processes that enable the natural evolution and selection of broadly neutralizing antibodies to HIV-1, providing a potential roadmap for the development of HIV-1 vaccine strategies to accelerate the induction of protective antibodies.
Alter, Galit, Barouch, Dan H.
openaire   +3 more sources

bNAber: database of broadly neutralizing HIV antibodies [PDF]

Nucleic Acids Research, 2013
The discovery of broadly neutralizing antibodies (bNAbs) has provided an enormous impetus to the HIV vaccine research and to entire immunology. The bNAber database at http://bNAber.org provides open, user-friendly access to detailed data on the rapidly growing list of HIV bNAbs, including neutralization profiles, sequences and three-dimensional ...
Alexey M. Eroshkin, Andrew LeBlanc, Dana Weekes, Kai W. Post, Zhanwen Li, Akhil Rajput, Sal T. Butera, Dennis R. Burton, Adam Godzik   +8 more
openaire   +6 more sources

Polyfunctionality of broadly neutralizing HIV-1 antibodies

Current Opinion in HIV and AIDS, 2023
Purpose of review The discovery of broadly neutralizing HIV-1 antibodies (bNAbs) has provided a framework for vaccine design and created new hope toward an HIV-1 cure. These antibodies recognize the HIV-1 Envelope and inhibit viral fusion with unprecedented breadth and potency. Beyond their unique neutralization capacity, bNAbs
Vrignaud, Lou-Léna, Schwartz, Olivier, Bruel, Timothée   +2 more
openaire   +4 more sources

An in vitro methodology for discovering broadly-neutralizing monoclonal antibodies [PDF]

Scientific Reports, 2020
AbstractBroadly-neutralizing monoclonal antibodies are of high therapeutic utility against infectious diseases caused by bacteria and viruses, as well as different types of intoxications. Snakebite envenoming is one such debilitating pathology, which is currently treated with polyclonal antibodies derived from immunized animals.
Ahmadi, Shirin; id_orcid 0000-0002-4131-583X, Pucca, Manuela B., Jürgensen, Jonas A.; id_orcid 0000-0002-8986-4483, Janke, Rahel, Ledsgaard, Line; id_orcid 0000-0001-7380-8420, Schoof, Erwin M.; id_orcid 0000-0002-3117-7832, Sørensen, Christoffer V.; id_orcid 0000-0001-7727-936X, Çalışkan, Figen, Laustsen, Andreas H.; id_orcid 0000-0001-6918-5574   +8 more
openaire   +4 more sources

Defining the impact of flavivirus envelope protein glycosylation site mutations on sensitivity to broadly neutralizing antibodies

mBio
Antibodies targeting an envelope dimer epitope (EDE) cross-neutralize Zika virus (ZIKV) and dengue virus (DENV) and have thus inspired an epitope-focused vaccine design. There are two EDE antibody subclasses (EDE1, EDE2) distinguished by their dependence
Maya Contreras, Jackson B. Stuart, Lisa M. Levoir, Laura Belmont, Leslie Goo   +4 more
doaj   +2 more sources

Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies.

PLoS Pathogens, 2019
Recently identified broadly neutralizing antibodies (bnAbs) show great potential for clinical interventions against HIV-1 infection. However, resistant strains may impose substantial challenges.
Panpan Zhou, Han Wang, Mengqi Fang, Yangyang Li, Hua Wang, Shasha Shi, Zihao Li, Jiapeng Wu, Xiaoxu Han, Xuanling Shi, Hong Shang, Tongqing Zhou, Linqi Zhang   +12 more
doaj   +2 more sources

Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1

Advanced Science
Broadly neutralizing antibodies are proposed as therapeutic and prophylactic agents against HIV‐1, but their potency and breadth are less than optimal.
Jianliang Xu, Tongqing Zhou, Krisha McKee, Baoshan Zhang, Cuiping Liu, Alexandra F. Nazzari, Amarendra Pegu, Chen‐Hsiang Shen, Jordan E. Becker, Michael F. Bender, Payton Chan, Anita Changela, Ridhi Chaudhary, Xuejun Chen, Tal Einav, Young Do Kwon, Bob C. Lin, Mark K. Louder, Jonah S. Merriam, Nicholas C. Morano, Sijy O'Dell, Adam S. Olia, Reda Rawi, Ryan S. Roark, Tyler Stephens, I‐Ting Teng, Emily Tourtellott‐Fogt, Shuishu Wang, Eun Sung Yang, Lawrence Shapiro, Yaroslav Tsybovsky, Nicole A. Doria‐Rose, Rafael Casellas, Peter D. Kwong   +33 more
doaj   +2 more sources

Broadly neutralizing monoclonal antibodies for HIV prevention [PDF]

Journal of the International AIDS Society, 2021
AbstractIntroductionThe last 12 years have seen remarkable progress in the isolation and characterization of at least five different epitope classes of HIV‐specific broadly neutralizing antibodies (bnAbs). Detailed analyses of these bnAb lineages, maturation pathways and epitopes have created new opportunities for vaccine development.
Maurine D. Miner, Lawrence Corey, David Montefiori   +2 more
openaire   +2 more sources

Broadly neutralizing antibodies, nonneutralizing antibodies and broadly effector antibodies to prevent HIV transmission? [PDF]

AIDS
Van de Perre P, Moore PL, Nagot N, Gama L, Moles JP.   +4 more
europepmc   +3 more sources